Remove 2009 Remove Communication Remove Vaccines
article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. During the 2009–19 period, children in the US ages five years and younger accounted for 58, 000 annual RSV-related hospitalisations and 100–500 annual deaths.

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

Active anti-Abeta immunotherapies In the 2000s, the concept of active immunotherapy targeting Abeta in Alzheimer’s patients was assessed with the ELAN vaccine (AN1792), consisting of full-length aggregated Abeta 1-42 peptide mixed with the QS21 adjuvant. 8 However, as this trial was not placebo-controlled, conclusions are difficult to draw.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A history of Johnson & Johnson

pharmaphorum

The company has also faced claims that it did not adequately communicate the risks of its opioid painkillers in its marketing, contributing to the US’ ‘opioid epidemic’, and that its talc products could contain small amounts of asbestos and lead to cancer. Litigation & controversy. billion the following February.

Vaccines 126
article thumbnail

Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease

pharmaphorum

She says she is “truly amazed” about what the industry has achieved in such a short time when it comes to innovations, vaccines and treatments. “When we come together like this, innovation can happen a lot faster.”. Connect with Dr Tunnah at [link] or [link].

Hospitals 111
article thumbnail

EMA Executive Director Speaks on the Value of Adaptation, Trust, & Collaboration

ISPE

Cooke, who has over 30 years of experience in international regulatory affairs, with 18 years in leadership roles, took the helm at EMA as director in November 2020, early in the pandemic, after having worked at EMA since 2002, serving as head of inspections initially and then as head of international affairs from 2009 to 2016.

article thumbnail

Why pharma needs a revolution in culture

pharmaphorum

He was referring to his business’ share of misconduct related fines that, between 2009 and 2017, topped $342 billion across the US and Europe. It’s killing us.”

article thumbnail

Contamination Trends & Proposed Solutions

ISPE

6 , 13 , 14 The most commonly mentioned contaminants were Burkholderia species 5 , 8 as a whole, and vesivirus 2117 for Genzyme products in 2009. Noteworthy cases were the inadvertent introduction of grade 316L stainless steel into Moder-na’s COVID-19 vaccine by the outsourced manufacturer (ROVI Pharma Industrial Services S.